Articles tagged with: Lexiva
Headline, News »
The Food and Drug Adminstration (FDA) and GlaxoSmithKline (GSK) added warnings of increased risk of heart attack and dyslipidemia (elevated cholesterol and lipid levels) to the prescribing information for Lexiva (fosamprenavir), an anti-HIV drug.
GSK, the drug’s manufacturer, has updated existing prescribing information to include the potential for Lexiva to increase cholesterol levels, which is known to raise the risk of heart attacks.
GSK recommends testing triglycerides and cholesterol levels in patients, both initially and at set intervals throughout the course of therapy.
Evidence for this increased risk comes from…